|
Agea
|
60 [26–82]
|
60 [32–79]
|
|
Gender/male (%)
|
266 (56.5)
|
65 (47.1)
|
|
Pre-operative CA 19-9 level (U/ml)a
|
199 [5.97–3015.17]
|
155.8 [11.7–1000]
|
|
Pre-operative CA 125 level (U/ml)a
|
22.5 [1.23–456.2]
|
22.0 [2.53–171.4]
|
|
Pre-operative CEA level (ng/ml)a
|
3.37 [0.2–113.5]
|
2.65 [0.2–113.5]
|
|
Pre-operative TB level (μmol/l)a
|
167.5 [1.9–753.1]
|
27.5 [1.9–34.2]
|
|
Pre-operative ALT level (U/l)a
|
102 [8–772]
|
86.5 [10–720]
|
|
Pre-operative AST level (U/l)a
|
90 [11–1016]
|
83 [11–523]
|
|
Pre-operative Albumin level (g/l)a
|
37.2 [18.7–51.8]
|
38.2 [28.8–50.1]
|
|
Tumor size (cm)a
|
3 [0.8–15]
|
2.8 [0.8–6]
|
|
Preoperative biliary drainage (%)
|
220 (46.7)
|
20 (14.5)
|
|
Bismuth–Corlette classification (%)
|
|
Type I and II
|
233 (49.5)
|
77 (55.3)
|
|
Type III and IV
|
238 (50.5)
|
61 (44.2)
|
|
T stage (AJCC) (%)
|
|
T1 and T2
|
218 (46.3)
|
82 (59.4)
|
|
T3 and T4
|
253 (53.7)
|
56 (40.6)
|
|
Surgical procedures (%)
|
|
Resected
|
309 (65.6)
|
98 (71.0)
|
|
Unresected
|
162 (34.4)
|
40 (29.0)
|
|
Postoperative complications (%)
|
137 (29.1)
|
32 (23.2)
|
